ICCM
IceCure Medical Ltd
Medical - Devices
Market Cap$10M
5Y Perf.-51.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
ICCM vs XTNT vs NVCR vs ATEC
Revenue, margins, valuation, and 5-year total return — side by side.
XTNT
Xtant Medical Holdings, Inc.
Medical - Devices
Market Cap$65M
5Y Perf.-63.5%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.84B
5Y Perf.-86.6%
ATEC
Alphatec Holdings, Inc.
Medical - Devices
Market Cap$1.16B
5Y Perf.-45.3%
ICCM vs XTNT vs NVCR vs ATEC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  ICCM |  XTNT |  NVCR |  ATEC |
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $10M | $65M | $1.84B | $1.16B |
| Revenue (TTM) | $4M | $122M | $674M | $595M |
| Net Income (TTM) | $-16M | $2M | $-173M | $-125M |
| Gross Margin | 36.5% | 62.3% | 75.2% | 89.6% |
| Operating Margin | -8.4% | 2.7% | -27.2% | -9.6% |
| Forward P/E | — | 15.3x | — | 25.4x |
| Total Debt | $217K | $29M | $290M | $620M |
| Cash & Equiv. | $9M | $17M | $103M | $161M |
ICCM vs XTNT vs NVCR vs ATEC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ICCM
XTNT
NVCR
ATEC
| Stock | Aug 21 | Jun 26 | Return |
|---|---|---|---|
| IceCure Medical Ltd (ICCM) | 100 | 49.0 | -51.0% |
| Xtant Medical Holdi… (XTNT) | 100 | 36.5 | -63.5% |
| NovoCure Limited (NVCR) | 100 | 13.4 | -86.6% |
| Alphatec Holdings, … (ATEC) | 100 | 54.7 | -45.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ICCM vs XTNT vs NVCR vs ATEC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTNT leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Alphatec Holdings, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. NVCR also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ICCM
IceCure Medical Ltd
The Secondary Option
ICCM lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
XTNT
Xtant Medical Holdings, Inc.
The Growth Play
XTNT carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 14.2%, EPS growth 125.0%, 3Y rev CAGR 32.2%
- Lower volatility, beta 0.70, Low D/E 56.4%, current ratio 2.65x
- Beta 0.70, current ratio 2.65x
- Lower P/E (15.3x vs 25.4x)
Best for: growth exposure and sleep-well-at-night
NVCR
NovoCure Limited
The Momentum Pick
NVCR is the clearest fit if your priority is momentum.
- -5.2% vs ICCM's -85.1%
Best for: momentum
ATEC
Alphatec Holdings, Inc.
The Income Pick
ATEC is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- beta 0.64
- 211.4% 10Y total return vs NVCR's 49.1%
- 25.0% revenue growth vs ICCM's 2.7%
- Beta 0.64 vs NVCR's 2.24
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ATEC | 25.0% revenue growth vs ICCM's 2.7% |
| Value |  XTNT | Lower P/E (15.3x vs 25.4x) |
| Quality / Margins | XTNT | 1.5% margin vs ICCM's -441.6% |
| Stability / Safety | ATEC | Beta 0.64 vs NVCR's 2.24 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  NVCR | -5.2% vs ICCM's -85.1% |
| Efficiency (ROA) | XTNT | 1.9% ROA vs ICCM's -119.1%, ROIC 8.1% vs -135.6% |
ICCM vs XTNT vs NVCR vs ATEC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
Segment breakdown not available.
FY 2025
ICCM vs XTNT vs NVCR vs ATEC — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTNTLAGGINGATEC
Who Leads Where
XTNT leads in 3 of 6 categories
ICCM leads 0 • NVCR leads 0 • ATEC leads 0 • 2 tied
Explore the data ↓ATECAlphatec Holdings, In…
0leads
NVCRNovoCure Limited
0leads
ICCMIceCure Medical Ltd
0leads
XTNTXtant Medical Holding…
3leads
6 Total Categories
CATEGORYLEADERvs ICCMvs NVCRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
XTNT3/6
Valuation MetricsMultiples, price ratios, and targets
XTNT3/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTNT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
XTNT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 189.2x ICCM's $4M. XTNT is the more profitable business, keeping 1.5% of every revenue dollar as net income compared to ICCM's -4.4%. On growth, ICCM holds the edge at +25.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric |  ICCMIceCure Medical L… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | ATECAlphatec Holdings… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $4M | $122M | $674M | $595M |
| EBITDAEarnings before interest/tax | -$29M | $8M | -$165M | $4M |
| Net IncomeAfter-tax profit | -$16M | $2M | -$173M | -$125M |
| Free Cash FlowCash after capex | -$15M | $8M | -$48M | $7M |
| Gross MarginGross profit ÷ Revenue | +36.5% | +62.3% | +75.2% | +89.6% |
| Operating MarginEBIT ÷ Revenue | -8.4% | +2.7% | -27.2% | -9.6% |
| Net MarginNet income ÷ Revenue | -4.4% | +1.5% | -25.7% | -21.1% |
| FCF MarginFCF ÷ Revenue | -4.3% | +6.4% | -7.1% | +1.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +25.7% | -36.5% | +12.3% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +6.6% | — | -100.0% | +37.1% |
XTNT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
XTNT leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, XTNT's 6.1x EV/EBITDA is more attractive than ATEC's 3727.7x.
| Metric | ICCMIceCure Medical L… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | ATECAlphatec Holdings… |
|---|---|---|---|---|
| Market CapShares × price | $10M | $65M | $1.8B | $1.2B |
| Enterprise ValueMkt cap + debt − cash | $2M | $76M | $2.0B | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -0.63x | 15.34x | -13.24x | -8.00x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 25.41x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 6.09x | — | 3727.73x |
| Price / SalesMarket cap ÷ Revenue | 3.02x | 0.48x | 2.80x | 1.52x |
| Price / BookPrice ÷ Book value/share | 1.07x | 1.35x | 5.29x | 31.99x |
| Price / FCFMarket cap ÷ FCF | — | 6.35x | — | 418.74x |
XTNT leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
XTNT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
XTNT delivers a 3.7% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-4 for ATEC. ICCM carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATEC's 17.21x. On the Piotroski fundamental quality scale (0–9), XTNT scores 8/9 vs ICCM's 3/9, reflecting strong financial health.
| Metric | ICCMIceCure Medical L… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | ATECAlphatec Holdings… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -2.1% | +3.7% | -50.8% | -4.4% |
| ROA (TTM)Return on assets | -119.1% | +1.9% | -16.5% | -15.8% |
| ROICReturn on invested capital | -135.6% | +8.1% | -16.4% | -12.6% |
| ROCEReturn on capital employed | -187.2% | +11.2% | -28.9% | -13.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 8 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.02x | 0.56x | 0.85x | 17.21x |
| Net DebtTotal debt minus cash | -$9M | $12M | $187M | $459M |
| Cash & Equiv.Liquid assets | $9M | $17M | $103M | $161M |
| Total DebtShort + long-term debt | $217,000 | $29M | $290M | $620M |
| Interest CoverageEBIT ÷ Interest expense | -313.68x | 2.07x | -96.80x | -3.29x |
XTNT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — XTNT and NVCR and ATEC each lead in 2 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ATEC five years ago would be worth $5,478 today (with dividends reinvested), compared to $139 for ICCM. Over the past 12 months, NVCR leads with a -5.2% total return vs ICCM's -85.1%. The 3-year compound annual growth rate (CAGR) favors XTNT at -11.8% vs ICCM's -48.2% — a key indicator of consistent wealth creation.
| Metric | ICCMIceCure Medical L… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | ATECAlphatec Holdings… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -75.9% | -38.7% | +23.1% | -63.0% |
| 1-Year ReturnPast 12 months | -85.1% | -31.9% | -5.2% | -39.3% |
| 3-Year ReturnCumulative with dividends | -86.1% | -31.3% | -80.4% | -50.1% |
| 5-Year ReturnCumulative with dividends | -98.6% | -71.1% | -92.1% | -45.2% |
| 10-Year ReturnCumulative with dividends | -98.6% | -98.2% | +49.1% | +211.4% |
| CAGR (3Y)Annualised 3-year return | -48.2% | -11.8% | -41.9% | -20.7% |
Evenly matched — XTNT and NVCR and ATEC each lead in 2 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NVCR and ATEC each lead in 1 of 2 comparable metrics.
Risk & Volatility
ATEC is the less volatile stock with a 0.64 beta — it tends to amplify market swings less than NVCR's 2.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs ICCM's 10.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ICCMIceCure Medical L… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | ATECAlphatec Holdings… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.85x | 0.70x | 2.24x | 0.64x |
| 52-Week HighHighest price in past year | $1.40 | $0.95 | $19.25 | $23.29 |
| 52-Week LowLowest price in past year | $0.13 | $0.44 | $9.82 | $6.82 |
| % of 52W HighCurrent price vs 52-week peak | +10.8% | +48.4% | +83.9% | +33.0% |
| RSI (14)Momentum oscillator 0–100 | 17.5 | 40.7 | 46.4 | 36.1 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 157K | 1.4M | 3.3M |
Evenly matched — NVCR and ATEC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: NVCR as "Buy", ATEC as "Buy". Consensus price targets imply 156.6% upside for ATEC (target: $20) vs 107.4% for NVCR (target: $34).
| Metric | ICCMIceCure Medical L… | XTNTXtant Medical Hol… | NVCRNovoCure Limited | ATECAlphatec Holdings… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | — | $33.50 | $19.71 |
| # AnalystsCovering analysts | — | — | 15 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTNT leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallXtant Medical Holdings, Inc. (XTNT)Leads 3 of 6 categories
Loading custom metrics...
ICCM vs XTNT vs NVCR vs ATEC: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ICCM or XTNT or NVCR or ATEC a better buy right now?
For growth investors, Alphatec Holdings, Inc.
(ATEC) is the stronger pick with 25. 0% revenue growth year-over-year, versus 2. 7% for IceCure Medical Ltd (ICCM). Xtant Medical Holdings, Inc. (XTNT) offers the better valuation at 15. 3x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ICCM or XTNT or NVCR or ATEC?
Over the past 5 years, Alphatec Holdings, Inc.
(ATEC) delivered a total return of -45. 2%, compared to -98. 6% for IceCure Medical Ltd (ICCM). Over 10 years, the gap is even starker: ATEC returned +200. 0% versus XTNT's -98. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ICCM or XTNT or NVCR or ATEC?
By beta (market sensitivity over 5 years), Alphatec Holdings, Inc.
(ATEC) is the lower-risk stock at 0. 64β versus NovoCure Limited's 2. 24β — meaning NVCR is approximately 248% more volatile than ATEC relative to the S&P 500. On balance sheet safety, IceCure Medical Ltd (ICCM) carries a lower debt/equity ratio of 2% versus 17% for Alphatec Holdings, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ICCM or XTNT or NVCR or ATEC?
By revenue growth (latest reported year), Alphatec Holdings, Inc.
(ATEC) is pulling ahead at 25. 0% versus 2. 7% for IceCure Medical Ltd (ICCM). On earnings-per-share growth, the picture is similar: Xtant Medical Holdings, Inc. grew EPS 125. 0% year-over-year, compared to 15. 0% for Alphatec Holdings, Inc.. Over a 3-year CAGR, XTNT leads at 32. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ICCM or XTNT or NVCR or ATEC?
Xtant Medical Holdings, Inc.
(XTNT) is the more profitable company, earning 3. 7% net margin versus -445. 6% for IceCure Medical Ltd — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: XTNT leads at 5. 4% versus -446. 7% for ICCM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ICCM or XTNT or NVCR or ATEC more undervalued right now?
Analyst consensus price targets imply the most upside for ATEC: 156.
6% to $19. 71.
07Which pays a better dividend — ICCM or XTNT or NVCR or ATEC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ICCM or XTNT or NVCR or ATEC better for a retirement portfolio?
For long-horizon retirement investors, Alphatec Holdings, Inc.
(ATEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 64), +200. 0% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 24 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ATEC: +200. 0%, NVCR: +51. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ICCM and XTNT and NVCR and ATEC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ICCM is a small-cap quality compounder stock; XTNT is a small-cap deep-value stock; NVCR is a small-cap quality compounder stock; ATEC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ICCM: 25.7% · XTNT: -36.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.